Swiss Diabetes Registry - SwissDiab Study (SwissDiab)

Swiss Diabetes Registry - SwissDiab Study, a Prospective Cohort Study of Patients With Diabetes in Switzerland

Currently, the estimated number of people with diabetes mellitus is approximately 387 million people worldwide. Due to population growth, urbanization, ageing and the rising prevalence of obesity the numbers of individuals with diabetes is increasing likewise. It has been shown that improving glycemic control is associated with a reduction in late complications of diabetes, such as cardiovascular and microvascular diseases. Therefore, treatment guidelines were established internationally by large and renowned associations and adopted by many countries.

For Switzerland only sparse data exist on the actual implementation of such recommendations and on patient's well-being. The Swiss Diabetes Registry - SwissDiab Study is a prospective cohort study aiming at including and collecting data of virtually all patients regularly seen and treated at the study centers (≈ 500 patients each), irrespective of type, duration of diabetes or treatment . This allows the evaluation of diabetes treatment strategies at these centers. Furthermore, risk indicators for micro- and macrovascular complications, mortality as well as costs and quality of life will be assessed. Data will be recorded through an internet-based, electronic database specifically designed for this study. At a later perspective it is planned to extend data collection to general practitioner/family doctor networks in order to include a larger and more representative sample of patients with diabetes in Switzerland.

Study Overview

• Status: Recruiting
• Conditions: Diabetes Mellitus

Detailed Description

Background

Currently, approximately 387 million people worldwide are affected by Diabetes Mellitus.

Due to population growth, urbanization, ageing and the rising prevalence of obesity the numbers of individuals with diabetes will grow. The American Diabetes Association estimated the total cost of diabetes in the US in 2012 at $245 billion. The greatest share of those costs results from the treatment of diabetes-associated complications caused by prolonged hyperglycemia. There is compelling evidence that tight glycemic control and intensive treatment of other cardiovascular risk factors substantially reduce the risk of developing being also cost-effective. Our current knowledge, however, is mainly derived from intervention trials usually including strictly defined patient groups and are carried out according to meticulous study protocols. Observational studies, however, in unselected outpatient settings have revealed discrepancies between recommended treatment goals resulting from those latter studies and actual standard of care. There is a pressing need, therefore, to assess the standard of care and confirm the feasibility and effectiveness of proposed management trends in both specialty clinic and community-based cohorts.

Objective

1. With the help of an internet-based, electronic database (webspirit®, www.swissdiab.ch): to collect representative cross-sectional data from all consenting patients seen and treated at the study centers in order to evaluate the current standard of care of patients with diabetes mellitus, the distribution of micro- and macrovascular complications, the use of medications and devices as well as aspects of costs and quality of life (QoL)
2. To collect prospective data of those patients in relation to achievement of treatment goals, changes in management, risk factors for, incidence and progression of micro- and macrovascular complications, mortality as well as costs and quality of life using the same database

Methods

After obtaining informed consent, patients with diabetes mellitus willing to participate will be invited to an initial comprehensive assessment (baseline) performed at the three cantonal study centers (Inselspital Bern, Kantonsspital St. Gallen, Universitätsspital Zürich). This will be followed by face-to-face clinical/laboratory visits between one to four times yearly according to patient's individual management plans. Once a year a comprehensive review including clinical and laboratory screening for diabetes-specific complications is planned.

• Study Type: Observational
• Enrollment (Estimated): 1500

Contacts and Locations

• Study Contact: Name: Markus Laimer, PD Dr. med.; Phone Number: +41 31 632 30 62; Email: Markus.Laimer@insel.ch
• Study Contact Backup: Name: Christoph Stettler, Prof.; Phone Number: +41 31 632 40 70; Email: christoph.stettler@insel.ch

Study Locations

• Switzerland
  • Bern, Switzerland, 3010
    • Recruiting
    • Universitätspoliklinik für Endokrinologie, Diabetologie und Klinische Ernährung, Inselspital Bern
    • Contact: Markus Laimer, PD Dr. med.; Phone Number: +41 31 632 30 62; Email: Markus.Laimer@insel.ch
    • Contact: Christoph Stettler, Prof.; Phone Number: +41 31 632 40 70; Email: christoph.stettler@insel.ch
    • Principal Investigator: Markus Laimer, PD Dr. med.
    • Sub-Investigator: Peter Diem, Prof.
    • Sub-Investigator: Katja Müller-Fischer, Dr. med.
  • Lausanne, Switzerland
    • Recruiting
    • Service d'endocrinologie, diabétologie et métabolisme
    • Contact: Valerie Schwitzgebel
  • St. Gallen, Switzerland, 9007
    • Recruiting
    • Klinik für Endokrinologie, Diabetologie, Osteologie und Stoffwechselerkrankungen, Kantonsspital St.Gallen
    • Principal Investigator: Michael Brändle, Prof. Dr. med., M.Sc.
    • Sub-Investigator: Katrin Schimke, Dr. med.
  • Zürich, Switzerland, 8091
    • Recruiting
    • Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich
    • Principal Investigator: Roger Lehmann, Prof. Dr. med.
    • Sub-Investigator: Jan Krützfeld, Prof. Dr. med.
    • Sub-Investigator: Giatgen Spinas, Prof. Dr. med.
    • Sub-Investigator: Philipp Gerber, PD Dr. med.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients with diabetes above age 18 are eligible for this study, irrespective of type, duration of diabetes or treatment. Diabetes will be defined according to the current diagnosis criteria suggested by the American Diabetes Association (fasting plasma glucose ≥ 7mmol/L, occasional plasma glucose ≥11.1mmol/L (plus typical symptoms), a 2hour plasma glucose of ≥11.1mmol/L after a 75g oral glucose tolerance test, or a HbA1c ≥ 6.5%), but patients under treatment with ≥2 oral hypoglycemic agents (OHA) and/or insulin in the absence of proof of a diagnosis by fasting, random plasma glucose or oral glucose tolerance test will also be included. The type of diabetes will be diagnosed clinically in most cases. In equivocal cases classification will be based on previously reported criteria with the assistance of laboratory test results.

Description

Inclusion Criteria:

• Age > 18 years
• Diagnosis of diabetes mellitus according to ADA criteria
• Informed consent

Exclusion Criteria:

• Patients with gestational diabetes mellitus, patients unable to give informed consent, legally incompetent or incapable to comply with the study terms and conditions as well as patients with significantly reduced life expectancy (<1 year) will be excluded

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
1; Patients with type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Mortality	annually

Secondary Outcome Measures

Outcome Measure	Time Frame
Macrovascular morbidity	annually
Microvascular morbidity	annually
Diabetes related influence on quality of Life	annually

Collaborators and Investigators

• Sponsor: Insel Gruppe AG, University Hospital Bern
• Collaborators: University of Zurich; Cantonal Hospital of St. Gallen
• Investigators: Principal Investigator: Michael Brändle, Prof., Div. of Endocrinology, Diabetes and Clinical Nutrition, Kantonsspital St. Gallen; Principal Investigator: Markus Laimer, PD Dr. med., Div. of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Bern; Principal Investigator: Roger Lehmann, Prof., Div. of Endocrinology, Diabetes and Clin. Nutrition, University Hospital Zürich

Study record dates

Study Major Dates

• Study Start: January 1, 2010
• Primary Completion (Estimated): January 1, 2099
• Study Completion (Estimated): January 1, 2099

Study Registration Dates

• First Submitted: August 10, 2010
• First Submitted That Met QC Criteria: August 10, 2010
• First Posted (Estimated): August 11, 2010

Study Record Updates

• Last Update Posted (Actual): September 1, 2023
• Last Update Submitted That Met QC Criteria: August 30, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Monogenetic diabetes; Cohort Studies; Patients with type 1 or type 2 diabetes mellitus; Pancreatogenic diabetes,; Drug-induced diabetes, other forms
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus
• Other Study ID Numbers: EKSG 01/114/L; EKSG 01/114/3B (Other Identifier: EC SG (previous number)); KEK 025/10 (Other Identifier: EC Bern (previous number))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No